Trial reportAmerican journal of hematology2019
Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
Trial report in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.British journal of haematology · 2026Pooled it
- Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.American journal of hematology · 2026Review
- Acoustic probing of new biomarkers for rapid sickle cell disease screening.Lab on a chip · 2026Article
- Article
- Birth Prevalence of Sickle Cell Disease in India: A Systematic Review and Meta-Analysis.International journal of neonatal screening · 2026Review
- Article
- Haemoglobin variants in nigeria: real-world data from a point-of-care device.Annals of hematology · 2025Article
- Diagnostic accuracy of HemoTypeSC for detecting sickle cell disease in newborns: A multicentric study.The Indian journal of medical research · 2025Article
- Disability and quality of life assessment using WHODAS-12 items 2.0 and EQ-5D-5L in a rural area endemic for loiasis in the Republic of Congo: A population-based cross-sectional study (the MorLo project).PLoS neglected tropical diseases · 2025Article
- Integration of newborn screening for sickle cell disease into primary health care in Bukavu, Democratic Republic of the Congo: a pilot study.BMC primary care · 2025Article
- Emerging Technologies and Advanced Strategies in Hemoglobin Defect Screening.Journal of clinical medicine · 2025Review
- Evaluation of low-cost techniques to detect sickle cell disease and β-thalassemia: an open-label, international, multicentre study.The Lancet regional health. Southeast Asia · 2025Article
- Protocol for a Multicentric Cohort Study on Neonatal Screening and Early Interventions for Sickle Cell Disease Among High-Prevalence States of India.Diagnostics (Basel, Switzerland) · 2025Article
- Association between Loa loa microfilaremia and anatomical hyposplenia in a rural area of the Republic of Congo: a population-based cross-sectional study.Infectious diseases of poverty · 2025Article
- Operational Feasibility of Point-of-Care Testing for Sickle Cell Disease in Resource-Limited Settings of Tribal Sub-Plan Region of India.Diagnostics (Basel, Switzerland) · 2025Article
- Newborn screening for sickle cell disease in Caluquembe, southwestern Angola, 2024-2025.PloS one · 2025Article
- Feasibility analysis of the SICKLECHECK™ test kit for rapid screening of sickle cell disease at a County Referral Hospital in Kenya.African journal of laboratory medicine · 2025Article
- Article
- A multiplexed, allele-specific recombinase polymerase amplification assay with lateral flow readout for sickle cell disease detection.Lab on a chip · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 6 countries.
Funding
Abstract
Sickle cell disease (SCD) is a common, life-threatening genetic disorder that is best managed when diagnosed early by newborn screening. However, SCD is most prevalent in low-resource regions of the world where newborn screening is rare and diagnosis at the point-of-care is challenging. In many such regions, the majority of affected children die, undiagnosed, before the age of 5 years. A rapid and affordable point-of-care test for SCD is needed. The diagnostic accuracy of HemoTypeSC, a point-of-care immunoassay, for SCD was evaluated in individuals who had SCD, hemoglobin C disease, the related carrier (trait) states, or a normal hemoglobin phenotype. Children and adults participated in low-, medium- and high-resource environments (Ghana [n = 383], Martinique [n = 46], and USA [n = 158]). Paired blood specimens were obtained for HemoTypeSC and a reference diagnostic assay. HemoTypeSC testing was performed at the site of blood collection, and the reference test was performed in a laboratory at each site. In 587 participants, across all study sites, HemoTypeSC had an overall sensitivity of 99.5% and specificity of 99.9% across all hemoglobin phenotypes. The test had 100% sensitivity and specificity for sickle cell anemia. Sensitivity and specificity for detection of normal and trait states were >99%. HemoTypeSC is an inexpensive (<$2 per test), accurate, and rapid point-of-care test that can be used in resource-limited regions with a high prevalence of SCD to provide timely diagnosis and support newborn screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.